ovarian-cancer
Platinum-resistant ovarian cancer has a median OS of less than 12 months with standard chemotherapy and few effective options. The ROSELLA trial tested a novel regimen combining niraparib (PARP inhibitor) with dostarlimab (anti-PD-1 antibody) in platinum-resistant disease, and an updated analysis…
ovarian-cancer
Low-grade serous ovarian cancer (LGSOC) is chemotherapy-resistant in many patients. The NRG-GY019 trial compared single-agent MEK inhibitor (trametinib) to combination chemotherapy in LGSOC. While the overall trial result was negative (combination chemotherapy did not demonstrate clear…
ovarian-cancer
Few environmental risk factors for ovarian cancer are known. This prospective study of 127,547 postmenopausal women in the Women's Health Initiative followed participants for up to 31 years, linking residential radon zone data to ovarian cancer incidence and mortality.
ovarian-cancer
A news roundup highlights several notable findings including a study from the Women's Health Initiative showing that high levels of residential radon — a naturally occurring radioactive gas that seeps into homes — were associated with approximately 30% higher risk of ovarian cancer in…
ovarian-cancer
First comprehensive drug testing platform for rare mucinous ovarian cancer reveals new treatment options Mucinous ovarian carcinoma (MOC) is a rare ovarian cancer subtype that behaves very differently from common high-grade serous ovarian cancer — and is treated poorly with the standard ovarian cancer regimens designed for the latter. A major
ovarian-cancer
Platinum-resistant ovarian cancer may be vulnerable to a microRNA-driven XIAP suppression strategy High-grade serous ovarian cancer (HGSOC) kills largely because it develops resistance to platinum-based chemotherapy. A core feature of resistant tumors is that cancer cells refuse to die even when chemotherapy signals are present. This study examined whether a